

Curriculum Vitae

Albert P. Li, Ph. D.

President and CEO

In Vitro ADMET Laboratories LLC

9221 Rumsey Road, Columbia, Maryland 21044

Telephone: (410)869-9037; Fax: (410)869-9034

Email: lialbert@invitroadmet.com

EDUCATION:

MBA (Executive) 2002, University of Maryland University College, College Park, Maryland

Ph.D. (Biomedical Sciences) 1976, Biology Division, Oak Ridge National Laboratory, University of Tennessee, Oak Ridge Graduate School of Biomedical Sciences

Doctoral Thesis: 3'-5'- Adenosine Monophosphate-Dependent Protein Kinase in Chinese Hamster Ovary Cells

Thesis Advisor: Dr. A. W. Hsie of Oak Ridge National Laboratory

B.Sc. (Chemistry (major)/Biology (minor)) 1972, University of Wisconsin, Stevens Point

PROFESSIONAL EXPERIENCE:

Present Positions :

Co-Founder, Chairman and CEO, In Vitro ADMET Laboratories, LLC, Rockville, MD (2004 – present)

Founder, Chairman, President and CEO, Advanced Pharmaceutical Sciences, Inc., Baltimore, MD (2004 – present)

Co-Founder, President and CEO, BRiVAL Inc., Vancouver, B. C., Canada (2008 to present)

Co-Founder, President and CEO, ALIVE Laboratories Inc., Albuquerque, New Mexico (2009 to present)

Previous Positions:

President and CEO, PHASE-1 Molecular Toxicology, Inc., Santa Fe, New Mexico (2002 – 2004)

Chief Scientific Officer, In Vitro Technologies, Inc., Baltimore, MD. (1998-2002);
Vice President, Hepatic Technologies, In Vitro Technologies, Inc. (1995-1998)
VP of Scientific Affairs, Stelsys LLC (an In Vitro Technologies Inc. Company)
Baltimore, MD (2000-2002)

Director, Surgical Research Institute and Research Professor,
Department of Surgery, St. Louis University Medical School
(1993-1995)

Senior Fellow and Head , Pharmacokinetics, Bioanalytical and Radiochemistry
Department (St. Louis Site), Monsanto Corporate Research and G. D. Searle & Co., a
subsidiary of Monsanto Company, St. Louis, 1993

Senior Fellow and Head, Liver Biology Department, Health Sciences Division,
Monsanto Corporate Research, Monsanto Company, St. Louis, MO
1992-1993

Fellow and Head, Liver Biology Department, Health Sciences Division, Monsanto
Corporate Research, Monsanto Company, St. Louis, MO
1990 to 1992

Fellow and Group Leader, Cellular and Genetic Toxicology Group -Environmental Health
Laboratory, Monsanto Company,
St. Louis, MO
1989-1990

Associate Fellow, Section Head, Molecular and Cellular Toxicology Section -
Environmental Health Laboratory, Monsanto Company, St. Louis, MO
1985-1989

Toxicology Research Specialist - Environmental Health Laboratory, Monsanto Company,
St. Louis, MO
1984-1985

Senior Research Toxicologist - Environmental Health Laboratory, Monsanto Company,
St. Louis, MO
1982-1984

Associate Scientist and Group Leader, Cellular and Genetic Toxicology , Inhalation
Toxicology Research - Lovelace Biomedical and Environmental Research Institute,
Albuquerque, NM
1979-1982

Research Scientist II, Research Assistant Professor - Cancer Research and Treatment Center, University of New Mexico Medical School, Albuquerque, NM
1977-1979

ACADEMIC APPOINTMENTS:

Director, Surgical Research Institute and **Research Professor**,
Department of Surgery, St. Louis University Medical School
(1993-1995)

Affiliate Professor, Department of Chemical Engineering,
Washington University, St. Louis, MO
1991-present

Visiting Professor, Department of Surgery, Hong Kong University, Queen Mary's
Hospital, Pokfulum Rd., Hong Kong.
1996

Adjunct Professor, Department of Pharmacology and Physiology, St. Louis University
Medical School, St. Louis, MO
1993-1995

Distinguished Visiting Professor, Institute of Chemical Carcinogenesis, Guangzhou
Medical College, Guangzhou, China
1990-Present

Adjunct Professor, Interdisciplinary Toxicology,
University of Arkansas Medical Center, Little Rock, AR
1985-1989

TEACHING APPOINTMENTS:

Biotransformation and Pharmacokinetics: Portion of Pharmacology course for
medical students, St. Louis University Medical School: 1993, 1994, 1995, 1996

Introduction To Cell and Tissue Culture. 3-credit graduate level course. Biology
Department, Washington University. (One semester per year; 1989, 1990, 1991, 1992,
1993, 1994)

Co-thesis advisor, Ph.D. dissertation committee of Mr. R. W. Shimizu, Biology
Department, New Mexico State University, Las Cruces, New Mexico. Dissertation title:
Genotoxicity of Inhaled Mutagens, 1980-1983

Co-thesis advisor, M.S. dissertation committee of Ms. Robyn Richards, Department of Biology, University of New Mexico, Albuquerque, New Mexico. Dissertation title: Protein Kinases in Bovine Thyroid, 1983-1986

Co-thesis advisor, Ph. D. dissertation committee of Mr. Tim Whitehead, Department of Chemical Engineering, Washington University, St. Louis, Missouri.
Dissertation Title: Modelling of a Bioartificial Liver

Postdoctoral Advisor for the following scientists:

Dr. Linda J. Loretz (1988-1990)

Dr. Jill Merrill (1989-1991)

Dr. Barrie Bode (1991 to 1993)

Dr. Dale Beck (1990 to 1994)

HONORS/AWARDS:

Wisconsin Legislative Scholarship (1969-1972).

Monsanto Achievement Award (1985)

Monsanto Searle Research Alert Award (1992)

Marquis Who's Who in Science and Engineering (1992-).

Marquis Who's Who in the Midwest (1993-)

Marquis Who's Who in Health Care (1997-)

Who's Who in International Professionals (1998-)

Recognition Award, Ciba Pharmaceuticals Preclinical Safety, U. S. Seminar Series, September 29, 1995

Certificate of Appreciation, Food and Drug Administration Coordinating Committee for Advanced Scientific Education, December 11, 1996

EDITORIAL BOARD:

Chemico-Biological Interactions (Section Editor), 1997- present

Journal of Toxicological Sciences – Japan (Associate Editor), 2000 - present

Current Drug Metabolism (Associate Editor) 2005 – present

Drug Metabolism Letters (Editorial Board) 2005 - present

Cell Biology and Toxicology (Editorial Board) 1997- present

Journal of Molecular Diversity (Editorial Board), 2002 - present

Mutation Research (Editorial Board) 1986-1996

EXTERNAL COMMITTEES AND MEMBERSHIPS:

Chair (2005 to present), Scientific Advisory Board, Institute for Scientific Exchange
Chair, Organizing Committee (1995 to present), International Conference on Drug-Drug Interactions, Institute for Scientific Exchange.

Chairman, Organizing Committee (2000 to present), International Conference on Early Toxicity Screening, Institute for Scientific Exchange

Subgroup Panel Member, ICCVAM-NICEATM/ECVAM/JaCVAM Scientific Workshop on Acute Chemical Safety Testing: Advancing *In Vitro* Approaches and Humane Endpoints for Systemic Toxicity Evaluations, February 6-7, 2008.

Review Panel Member, ICCVAM In Vitro Pyrogenicity Peer Panel, NICEATM-ICCVAM, February 6, 2007.

Chairman, Steering Committee, Hepatocyte Users Group of North America, 1996-2002

Member, Organizing Committee, 1996 DIA International Symposium on Drug-Drug Interactions, 1996.

Chairman, Ad Hoc International Expert Panel for the Application of Human Hepatocytes in the Evaluation of Cytochrome P450 induction, 1996-1997.

Member, American Association for Pharmaceutical Scientists, 1998-present.

Member, Society for Biomolecular Screening, 1998-present.

Member, Society of Toxicology, 1982-present.

Member, International Society for the Study of Xenobiotics, 1991-present.

Member, Environmental Mutagen Society, 1980-present.

Member, American Society for Artificial Internal Organs, 1994-1996.

Counselor, Environmental Mutagen Society, 1990 to 1993.

Panel Member, International Workshop on Human in vitro Liver Preparations for Metabolism Studies in Drug Development, 1994.

Panel Member, Predicting Drug Toxicity, National Academy of Sciences Institute of Medicine, 1993.

Committee Member, Environmental Mutagen Society, Future Directions Committee, 1991 to 1992.

Co-chairman, American Industrial Health Council Mutagenicity Subcommittee, 1990-1991.

Chairman, Environment Mutagen Society Committee on Exhibits, Sponsors, and Sustaining Members, 1990-1993.

Committee Member, Environmental Mutagen Society Program Committee, 1990-1991.

Chairman, Environmental Mutagen Society Workshop on the Application of Mammalian Cells in Industrial Genotoxicity Testing, 1989-90.

Chairman, ad hoc round table meeting with industrial and regulatory representatives on the Role of Mammalian Gene Mutation Assays in Chemical Toxicity Evaluation, May 1988.

Chairman, Environmental Mutagen Society Workshop on the Evaluation of Nongenotoxic Carcinogens, 1988.

Panel Member, NIEHS, Phase I of the Superfund Hazardous Substances Basic Research Program, 1987.

Panel Member, Peer Review Panel for the Genetic Toxicology Division, US EPA Health Effects Research Laboratory, August 1986.

Chairman, EPA Phase III Gene-Tox Program for CHO/HGPRT Gene Mutation Assay, 1985-1989.

Chairman, ASTM CHO/HGPRT Workgroup for the Establishment of Testing Guidelines, 1984-1989.

Chairman, Environmental Mutagen Society Workshop on Research Needs in the Genotoxicity Testing of Industrial Chemicals, 1986.

Chairman, NIEHS SBIR Review Committee for Oncogene Research, February 1986.

Panel Member, NIEHS SBIR Review Committee for Cell Biology Research, 1985.

Panel Member, Chemical Manufacturers Association Workshop Panel on Indices of Data Documentation of In Vitro Systems, 1984.

Panel Member, EPA Review Committee on Health Effects of Fuels and Fuel Additives, 1983.

Chairman, Environmental Mutagen Society Workshop on the Application of CHO Cells in Industrial Toxicology, 1983-1984.

Member, American Society of Testing Materials, E47.09 Genetic Toxicology Subcommittee, 1983-1989.

Panel Member, Review Panel for Grant Proposals on Cellular and Biochemical Markers Related to Non-Neoplastic Lung Disease, 1982.

PATENTS

Biological Artificial Liver: U. S. Patent Application serial number, 07/832,461; filed 02/07/92; found allowable in June, 1993, published Dec., 1993.

Artificial liver apparatus and method: U. S. Patent Application serial number, **6,858,146**; filed 02/20/02; allowed and published Feb. 22, 2005.

Cell Culture Tool and Method: U. S. Patent No. US 7,186,548 B2; Date of Patent: March 6, 2007.

Cell Culture Tool and Method: The People's Republic of China Patent No. 626030; Date of Patent: May 26, 2010.

Cell Culture Tool and Method: Japan patent (allowed in September, 2010).

EXTERNAL PUBLICATIONS: PAPERS

1. **A. P. Li**, K. Kawashima, and A. W. Hsie. *In vivo* activation of cyclic adenosine 3':5' Adenosine Monophosphate-Dependent Protein Kinase in Chinese Hamster Ovary Cells

- treated with N6, O2'-dibutyryl cyclic adenosine 3':5'; monophosphate.* Biochem. Biology. Res. Com. 64(2): 507-513 (1975).
2. A. W. Hsie, J. P. O'Neill, C. H. Schroeder, K. Kawashima, L. S. Borman, and **A. P. Li**. *Action of adenosine 3':5'-phosphate in Chinese hamster ovary cells.* In: Control Mechanism in Cancer (W. E. Criss, T. Ono, and J. R. Sabine, eds.), Raven Press, New York, pp. 183-203 (1976).
 3. A. W. Hsie, J. P. O'Neill, **A. P. Li**, L. S. Borman, C. H. Schroeder and K. Kawashima. *Control of cell shape of adenosine 3':5'-phosphate in Chinese hamster ovary cells: Studies of cyclic nucleotide analogue action, protein kinase activation and microtubule organization. Differentiation and Carcinogenesis.* In: Advances in Pathobiology (C. Borek, C. M. Fenoglio, D. W. King, eds.), Stratton Intercontinental Medical Book Incorp., New York (1977).
 4. **A. P. Li**, J. P. O'Neill, K. Kawashima, and A. W. Hsie. *Correlation between changes of intracellular level of cyclic AMP, activation of cyclic AMP-dependent protein kinase and the morphology of Chinese hamster ovary cells.* Arch. Biochem. Biophys. 182: 181-187 (1977).
 5. J. P. O'Neill, **A. P. Li**, and A. W. Hsie. *Action of cyclic nucleotide analogues in Chinese hamster ovary cells.* Biochem. Biophys. Acta. 497: 35-45 (1977).
 6. **A. P. Li** and A. W. Hsie. *Properties and subcellular distribution of cyclic AMP-dependent protein kinases in Chinese hamster ovary cells.* Biochem. Biophys. Acta. 500: 140-151 (1977).
 7. A. W. Hsie, **A. P. Li**, and R. Machanoff. *A fluence-response study of lethality and mutagenicity of white, black and blue fluorescent light, sunlamp, and sunlight irradiation in Chinese hamster ovary cells.* Mutation Res. 45: 333-342 (1977).
 8. A. W. Hsie, D. B. Couch, J. P. O'Neill, J. R. San Sabastian, P. A. Brimer, R. Machanoff, J. C. Riddle, **A. P. Li**, J. C. Fuscoe, N. Forbes, M. H. Hsie. *Utilization of a quantitative mammalian cell mutation system in experimental mutagenesis and genetic toxicology.* In: Strategy for Short-Term for Mutagens/Carcinogens (B. Butterworth, ed.), R. C. Press Incorp., West Palm Beach, FL, pp. 39-54 (1979).
 9. A. W. Hsie, J. P. O'Neill, D. B. Couch, J. R. San Sabastian, P. A. Brimer, R. Machanoff, J. C. fuscoe, J. C. Riddle, **A. P. Li**, N. L. Forbes, M. H. Hsie. *Quantitative analysis of radiation and chemical induced lethality and mutagenesis in Chinese hamster ovary cells.* Radiation Res. 76: 471-492 (1977).
 10. J. M. Yuhas, **A. P. Li**, A. O. Martinez, and A. J. Ladman. *A simplified method for production and growth of multicellular tumor spheroids.* Cancer Res. 37: 3639-3643 (1977).

11. J. M. Yuhas, and **A. P. Li**. *In vitro* studies on the radioresistance of oxic and hypoxic cells in the presence of both radioprotective and radiosensitizing drugs. *Radiation Res.* 75: 563-572 (1978).
12. **A. P. Li** and A. W. Hsie. *Characterization of two species of cyclic AM-dependent protein kinase in Chinese hamster ovary cells*. *Biochem. Biophys. Acta.* 527: 403-413 (1978).
13. J. M. Yuhas and **A. P. Li**. *Growth fraction as the major determinant of Multi-cellular tumor spheroid growth rate*. *Cancer Res.* 38: 1528-1532 (1978).
14. J. M. Yuhas, **A. P. Li**, and M. M. Kligerman. *Present status of the proposed use of negative pi mesons in radiotherapy*. In: *Advances in Radiation Biology*, Vol. 8 (J. T. Lett, H. Adler, eds.), Academic Press, New York, pp. 51-58 (1979).
15. **A. P. Li**. *Growth of mammalian cells as unattached cultures on nontissue culture plates*. *J. Tissue Culture Methods* 6: 71-74 (1980).
16. L. Elias, **A. P. Li**, and J. Longmire. *Cyclic Adenosine 3':5'-Monophosphate-dependent and -independent protein kinase in acute myeloblastic leukemia*. *Cancer Res.* 41: 2182-2188 (1981).
17. **A. P. Li**. *Simplification of the CHO/HGPRT mutation assay through the growth of Chinese hamster ovary cells as unattached cultures*. *Mutation Res.* 85: 165-175 (1981).
18. **A. P. Li**. *Antagonistic effects of animal sera, lung and liver cytosols, and sulfhydryl compounds on the cytotoxicity of diesel exhaust particle extracts*. *Toxicol. Appl. Pharmacol.* 57: 55-62 (1981).
19. T. R. Henderson, **A. P. Li**, R. E. Royer, and C. R. Clark. *Increased cytotoxicity and mutagenicity of diesel fuel after reaction with NO₂*. *Environ. Mutag.* 3: 211-220 (1981).
20. **A. P. Li** and A. L. Brooks. *Use of Chinese hamster ovary cells in the evaluation of potential hazards from energy effluents application to diesel exhaust emission*. In: *Proceedings of the International Symposium of Health Impacts of Different Sources of Energy* (M. Lewis, ed.), International Atomic Energy Agency Press, Vienna, pp. 350-355 (1981).
21. C. R. Clark and **A. P. Li**. *Genetic toxicology A. Microbial and mammalian cell systems for detecting mutagens*. *Proceedings of The American College of Veterinary Toxicologist Workshop*, Amex, Iowa, (1981).
22. **A. P. Li** and R. E. Royer. *Diesel exhaust particle extract enhancement of chemical-induced metagenesis in cultured Chinese hamster ovary cells: Possible interaction of diesel exhaust with environmental carcinogens*. *Mutation Res.* 103: 349-355 (1982).

23. **A. P. Li.** *Quantitation of mutation at the Na⁺-K⁺-ATPase and hypoxanthine-guanine phosphoribosyl transferase gene locus in Chinese hamster ovary cells* J. Tissue Culture Methods 7: 27-32 (1982).
24. **A. P. Li,** A. R. Dahl, and J. O. Hill. *In vitro cytotoxicity and genotoxicity of dibutyltin dichloride and dibutylgermanium dichloride.* Toxicol. Appl. Pharmacol. 64: 482-485 (1982).
25. P. O. Zamora, P. E. Gregory, **A. P. Li,** and A. L. Brooks. *An in vitro model for the exposure of lung alveolar epithelial cells of toxic gases.* J. Environ. Toxicol. Path. Oncol. (1982).
26. T. C. Marshall, R. E. Royer, **A. P. Li,** D. F. Kusewitt and A. L. Brooks. *Acute and genetic toxicity of 1-nitropyrene and its fate following single oral doses to rats.* J. Toxicol. and Environ. Health 10: 373-384 (1982).
27. **A. P. Li,** R. E. Royer, A. L. Brooks, and R. O. McClellan. *Cytotoxicity of diesel exhaust particle extract: A comparison of five cars of different manufacturers.* Toxicology 24: 1-8 (1982).
28. **A. P. Li,** A. L. Brooks, C. R. Clark, R. W. Shimizu, R. L. Hanson, J. S. Dutcher. *Mutagenicity testing of complex environmental mixtures with Chinese hamster ovary cells.* In: Short-Term Bioassays in the Analysis of Complex Environmental Mixtures III (M. D. Waters, S. D. Sandhu, J. Lewtas, L. Claxton, N. Chernoff and S. Nesnow eds.), Plenum Press, New York, pp. 183-196 (1983).
29. **A. P. Li,** F. F. Hahn, P. O. Zamora, R. W. Shimizu, R. F. Henderson, A. L. Brooks, and R. Richards. *Characterization of a lung epithelial cell strain with potential applications in toxicology.* Toxicology 27: 257-272 (1983).
30. **A. P. Li** and J. S. Dutcher. *Mutagenicity of mono-, di-, tri-nitropyrenes in Chinese hamster ovary cells.* Mutation Res. 119: 381-386 (1983).
31. J. A. Bond and **A. P. Li.** *Rat nasal activation of benzo(a) pyrene and 2-animoanthracene to mutagens in Salmonella typhimurium.* Environ. Mutag. 5: 311-318 (1983).
32. **A. P. Li,** C. R. Clark, R. L. Hanson, T. R. Henderson, and C. H. Hobbs. *Comparative mutagenicity of a coal combustion fly ash extract in Salmonella typhimurium and Chinese hamster ovary cells.* Environ. Mutag. 5: 263-272 (1983).
33. T. R. Henderson, J. D. Sun, R. E. Royer, C. R. Clark, **A. P. Li,** T. M. Harvey, D. F. Hunt, J. E. Fulfund, W. R. Davidson. *Triple-quadruple mass spectrometry studies of nitroaromatic emission from different diesel engines.* Environ. Sci. and Technol. 17: 443-449 (1983).
34. K. S. Engwall and **A. P. Li.** *Isolation and Culturing of Rat Alveolar Macrophages.* J. Tissue Culture Methods 8: 91-94 (1983).

35. **A. P. Li** and R. W. Shimizu. *A modified agar assay for the quantitation of mutation in Chinese hamster ovary cells*. Mutation Res. 111: 365-370 (1983).
36. P. O. Zamora, **A. P. Li**, J. M. Benson and A. L. Brooks (1983). *Evaluation of an exposure system using cells grown on collagen for detecting highly volatile mutagens in the CHO/HGPRT system*. Environ. Mut. 5: 795-802 (1983).
37. P. O. Zamora, J. M. Benson, T. C. Marshall, B. V. Mokler, **A. P. Li**, A. R. Dahl, A. L. Brooks and R. O. McClellan. *Cytotoxicity and mutagenicity of vapor phase environmental pollutants in rat lung epithelial cells and Chinese hamster ovary cells*. J. Toxicol. Environ. Health 12: 27-38 (1983).
38. T. R. Henderson, J. D. Sun, R. E. Royer, C. R. Clank, **A. P. Li**. *Triple-quadruple mass spectrometry studies on nitroaromatic emissions from different diesel engines*. Environ. Sci. Technol. 17: 443-449 (1983).
39. **A. P. Li**, J. D. Sun, and C. E. Mitchell. *Possible biological fate of inhaled pollutants: Interactions with biological molecules and chemical carcinogens*. In: Synthetic Fossil Fuel Technologies (K. E. Cowser and R. Richmand, eds.), Butterworths Publishers, 80 Montvale Avenue, Stoneham, pp. 403-416 (1984).
40. T. R. Henderson, J. D. Sun, **A. P. Li**, R. L. Hanson and W. E. Bechtold. *GC/MS and MS/MS studies on diesel exhaust mutagenicity and emissions from chemically defined fuels*. Environ. Sci. Technol. 18: 428-434 (1984).
41. W. E. Bechtold, J. S. Dutcher, B. V. Mokler, J. A. Lopez, I. Wolf, **A. P. Li**, T. R. Henderson and R. O. McClellan. *Chemical and biological properties of diesel exhaust particles collected during selected segments of a simulated driving cycle*. Fund. Appl. Toxicol. 4: 370-377 (1984).
42. R. W. Shimizu, J. D. Sun, A. L. Brooks, and **A. P. Li**: *The use of sister chromatid exchange in Chinese hamster primary lung cell cultures to measure genotoxicity*. Mutation Res 130: 333-342 (1984).
43. A. L. Brooks, R. W. Shimizu, **A. P. Li**, J. M. Benson, and J. S. Dutcher. *The induction of sister chromatid exchanges by environmental pollutants*; proceedings, International Symposium on SCE, Bartella National Lab. (1984).
44. A. L. Brooks, **A. P. Li**, J. S. Dutcher, C. R. Clark, S. J. Rotherberg, R. Kiyoura, W. E. Bechtold, and R. O. McClellan. *A comparison of genotoxicity of automobile exhaust particles from laboratory and environmental sources*. Environ. Mut. 6: 651-668 (1984).
45. R. W. Shimizu, J. M. Benson, **A. P. Li**, R. F. Henderson, and A. L. Brooks. *Evaluation of the genotoxicity of process stream extracts from a coal gasification system*. Environ. Mut. 6: 825-834 (1984).

46. **A. P. Li.** *Use of Aroclor 1254-induced rat liver homogenate in the assaying of promutagens in Chinese hamster ovary cells.* Environ. Mut. 6: 539-544 (1984).
47. **A. P. Li.** *A Testing Strategy to Evaluate the Mutagenic Activity of Industrial Chemicals.* Regulatory Toxicol. Pharmacol. 5: 207-211 (1985).
48. **A. P. Li,** T. L. Blank, D. K. Flaherty, W. E. Ribelin and A. G. E. Wilson. *Toxicity Testing: New Approaches and Applications in Human Risk Assessment.* Raven Press, New York (1985).
49. **A. P. Li.** *An in vitro lung epithelial cell system for evaluating the potential of inhalable materials.* Fd. Chem. Toxic. 24: 527-534 (1986).
50. **A. P. Li,** J. H. Carver, W. N. Choy, A. W. Hsie, R. S. Gupta, K. S. Loveday, J. P. O'Neill, J. C. Riddle, L. F. Stankowski, Jr. and L. L. Yang. *A guide for the performance of the Chinese hamster ovary cell/hypoxanthine guanine phosphoribosyl transferase gene mutation assay.* Mutat. Res. 189: 135-141 (1987).
51. **A. P. Li,** R. S. Gupta, R. H. Heflich and J. S. Wassom. *A review and analysis of the Chinese hamster ovary/hypoxanthine guanine transferase assay to determine the mutagenicity of chemical agents.* A report of Phase III of the U. S. Environmental Protection Agency Gene-Tox program. Mutat. Res. 196: 17-36 (1988).
52. **A. P. Li,** and C. A. Myers. *In vitro evaluation of the cytotoxic potential of a novel manmade fiber, calcium sodium metaphosphate fiber (phosphate fiber).* Fund. App. Tox. 11: 21-28 (1988).
53. **A. P. Li,** and T. J. Long. *An evaluation of the genotoxic potential of glyphosate.* Fund. Appl. Tox. 10: 537-546 (1988).
54. L. J. Loretz, A. G. E. Wilson, and **A. P. Li.** *Promutagen activation by freshly isolated and cryopreserved rat hepatocytes.* Environmental and Molecular Mutagenesis 12: 335-341 (1988).
55. L. J. Loretz, **A. P. Li,** M. W. Flye and A. G. E. Wilson. *Optimization of cryopreservation procedures for rat and human hepatocytes.* Xenobiotica 19: 489-498 (1989).
56. **A. P. Li.** *Spontaneous frequency of 6-thioguanine resistant mutants in CHO-AS52 cells after prolonged culturing in the absence of selective agents.* Environmental and Molecular Mutagenesis 15: 214-217 (1990).
57. R. E. Kane, J. Tector, J. J. Brems, **A. P. Li** and D. L. Kaminski. *Sulfation and glucuronidation of acetaminophen by cultured hepatocytes replicating in vivo metabolism.* ASAIO Transactions 36: 607-610 (1990).

58. **A. P. Li**, C. S. Aaron, A. E. Auletta, K. L. Dearfield, J. C. Riddle, R. S. Slesinski and L. F. Stankowski, Jr. *An evaluation of the roles of mammalian cell mutation assays in the testing of chemical genotoxicity*. *Regulatory Toxicol. Pharmacol.* 14: 24-40 (1991).
59. **A. P. Li** and L. D. Kier. *Overview: Industrial perspectives on existing in vivo gene mutation assays*. *Environ. Mol. Mutag.* 18: 292-294 (1991).
60. **A. P. Li**, C. A. Myers, M. A. Roque and D. L. Kaminski. *Epidermal growth factor, DNA synthesis and human hepatocytes*. *In Vitro Cell. Dev. Biol.* 27: 831-833 (1991).
61. **A. P. Li** and L. J. Loretz. *Assays for genetic toxicity*. In: *Genetic Toxicology* (**A. P. Li** and R. H. Heflich, eds.), CRC Press, Boca Raton (1991).
62. R. E. Kane, J. Tector, J. J. Brems, **A. P. Li**, and D. Kaminski. *Sulfation and glucuronidation of acetaminophen by cultured hepatocytes reproducing in vivo sex-differences in conjugation on Matrigel and Type 1 collagen*. *In Vitro Cell. Dev. Biol.* 27A: 953-960 (1991).
63. **A. P. Li** and A. G. Teepe. *Application of cultured lung cells in toxicology and xenobiotic metabolism*. In: *In Vitro Methods in Toxicology and Pharmacology* (R. Watson, ed.) CRC Press, Boca Raton, pp. 253-268, (1992).
64. R. S. Nair, **A. P. Li**, R. N. Shiotsuka and A. G. E. Wilson. *Toxicity testing program of a novel fiber: I. In vitro and in vivo degradation and clearance studies with calcium sodium metaphosphate fiber*. *Fund. Appl. Toxicol.* 19: 69-78 (1992).
65. **A. P. Li**, M. A. Roque, D. J. Beck and D. L. Kaminski. *Isolation and culturing of hepatocytes from human liver*. *J. Tiss. Culture Methods* 14: 139-146 (1992).
66. U. S. Ryan and **A. P. Li**. *Metabolism of endogenous and xenobiotic substances by pulmonary vascular endothelial cells*. In: *Metabolic Activation and Toxicity of Chemical Agents to Lung Tissue and Cells* (Gram, T.E. ed.) Pergamon Press Ltd., Oxford, pp. 107-122 (1992).
67. **A. P. Li**, C. A. Myers, D. L. Kaminski. *Gene transfer in primary cultures in human hepatocytes*. *In Vitro Cell. Dev. Biol.* 28A: 373-375 (1992).
68. A. G. Teepe, D. J. Beck and **A. P. Li**. *A comparison of rat liver parenchymal and nonparenchymal cells in the activation of promutagens*. *Environ. Mol. Mutagenesis* 20: 134-139 (1992).
69. **A. P. Li**, S. M. Colburn and D. J. Beck. *A simplified method for the culturing of primary adult rat and human hepatocytes as multicellular spheroids*. *In Vitro Cell. Dev. Biol.* 28A: 673-677 (1992).
70. **A. P. Li** and A. G. Teepe (1992). *Applications of cultured lung cells in toxicology*. In: *In Vitro Methods of Toxicology* (R. Watson, Ed.). CRC Press, Boca Raton, Florida. Pp. 253-268

71. **A. P. Li**, G. Barker, D. Beck, S. Colburn, R. Monsell and C. Pellegrin. *Culturing of primary hepatocytes as entrapped aggregates in a packed bed bioreactor: A potential bioartificial liver.* In Vitro Cell. Dev. Biol. 29A:249-254 (1993).
72. S. M. Moerlein, R. A. Weisman, D. Beck, **A. P. Li** and M. J. Welch (1993). *Metabolism in vitro of radioiodinated N-isopropyl-para-iodoamphetamine by cultured hepatocytes.* Nucl. Med. Biol. 20: 49-56 (1993).
73. **A. P. Li**, C. S. Aaron, L. F. Stankowski, Jr., M. M. Moore and J. S. Warsom. *A review and analysis of the Chinese hamster ovary cell-AS52/guanine phosphoribosyl transferase assay to determine the mutagenicity of chemical agents.* A report of Phase III of the U. S. Environmental Protection Agency Gene-Tox program. Mutation Research (in preparation).
74. **A. P. Li.** *Primary hepatocyte culture as an in vitro toxicological system.* In: In Vitro Toxicology (Shayne Gad, ed.) Raven Press, New York, New York. Pp. 195-220 (1994).
75. K. Lee, Y. Vandenberghe, M. Herin, R. Cavalier, D. Beck, **A. Li**, N. Verbekes, M. Lesne and J. Roba. *Comparative metabolism of SC-42867 and SC-51089, two PGE₂ antagonists, in rat and human hepatocyte cultures.* Xenobiotica 24: 25-36 (1994).
76. D. L. Kaminski, Amir, G., Deshpande, Y. G., Beck, D., and **Li, A. P.** (1994). Studies on the etiology of acute acalculous cholecystitis: The effect of lipopolysaccharide on human gallbladder mucosal cells. Prostaglandins 47: 319-330.
77. J. C. Merrill, D. J. Beck, D. L. Kaminski and **A. P. Li.** (1995). Polybrominated biphenyl induction of cytochrome P450 mixed function oxidase activity in primary rat and human hepatocytes. Toxicology 99/3:147-152.
78. Williams, J., **Li, A.**, Fairchild, R., Soloman, H., Kaminski, D. L. (1995). Effect of cyclosporine A and G and FK506 on basal and growth factor mediated DNA synthesis by normal human hepatocytes. Surgical Research Communications (In press).
79. Stratton, M., Longo, W. E., chandel, B., Deshpande, Y., **Li, A. P.**, Vernava, A. M., Kaminski, D. L. (1994). The effect of clostridium difficile toxin on colonocyte prostanoid formation. Prostaglandins 48:367-375.
80. Nag, M. K., Deshpande, Y. G., Beck, D., **Li, A.**, and Kaminski, D. L. The effect of lysolecithin on prostanoid and platelet-activating factor formation by human gallbladder mucosal cells. Mediators of Inflamm. (In press)
81. Kaminski, D. L., Deshpande, Y. G., **Li, A.**, Dysart, F., and Nag, M. (1995) Gallbladder mucosal protein secretion during the development of experimental cholecystitis. Digestive Dis. Sc. 40:1157-1164.

82. Sexe, R. B., Longo, W. E., Kaminski, D. L., and **Li, A. P.** (1995) Isolation and culturing of primary human colonocytes. *Methods in Cell Science* 17: 195-198.
83. Kane, R. E., **Li, A. P.**, and Kaminski, D. R. (1995). Sulfation and glucuronidation of acetaminophen by human hepatocytes cultured on matrigel and type 1 collagen reproduces conjugation in vivo. *Drug Metabol. Disp.* 23:303-307.
84. **Li, A. P.**, Xu, L., Rasmussen, A., Kaminski, D. L. (1995). Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. *J. Pharmacol. Exp. Therap.* 274:673-677
85. Roth, W. L., Beck, D. L., Holm, R. D., McCormick, M. A., **Li, A. P.**, and Wilson, A. G. E. Metabolism of p-dichlorobenzene by hepatocytes in vitro. Comparison of first-order series with "pipeline" reaction mechanisms using a mathematical model of culture. (Submitted)
86. Kier, L. D., Wagner, L. M., Wilson, T. V., **Li, A. P.**, Short, R. D., and Kennedy, G. L. (1995). Cytotoxicity of ethylene oxide/propylene oxide copolymers in cultured mammalian cells. *Drug Chem. Toxicol.* 18: 29-41.
87. Soloman, H., Contis, J., **Li, A. P.**, Kaminski, D. L. (1996). The effect of prostanoids on hepatic bile flow in dogs with normal liver and bile duct cell hyperplasia. *Prostaglandins Leukot. Essent. Fatty Acids* 54:265-271.
88. Kaminski, D. L., Roque, M. A., **Li, A. P.** (1996). Role of protein kinase A in human hepatocyte DNA synthesis. *Dig Dis Sci* 41:1014-1021.
89. Stratton, M. D., Sexe, R., Peterson, B., Kaminski, D. L., **Li, A. P.**, Longo, W. E. (1996). The effect of trinitrobenzene sulfonic acid (TNB) on colonocyte arachidonic acid metabolism. *J Surg Res* 60:375-378.
90. **Li, A. P. (1997)**. Evaluation of drug-drug interactions in primary human hepatocytes . In: *Drug-drug Interactions: Scientific and Regulatory Perspectives*, A. P. Li, Volume Editor. *Advances in Pharmacology*, 43: 103-130.
91. **Li, A. P.** (1998). Applications of primary hepatocytes in drug metabolism and toxicology. *Comments on Toxicology*, 6: 199-220.
92. **Li, A. P.**, Maurel, J. P., Lechon-Gomez, M., Cheng, L. C. and Jurima-Romet, M. (1997). Preclinical evaluation of drug-drug interactions: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. *Chemico-Biological Interactions* 107:5-16
93. Mattes, W. B. and **Li, A. P.** (1997). Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. *Chemico-Biological Interactions* 107:47-61.

94. **Li, A. P.** and Kedderis, G. L. (1997). Primary hepatocyte culture as an experimental model for the evaluation of interactions between xenobiotics and drug-metabolizing enzymes. *Chemico-Biological Interactions* 107:1-3.
95. Ruegg, C. E., Silber, P. M., Mughal, R. A., Ismail, J., Lu, C. and **Li, A. P.** (1997) P450 induction in primary human hepatocytes after cryopreservation. *In Vitro Toxicology* 10:217-222.
96. Jurima-Romet, M., Huang, H. S., Beck, D. J. and **Li, A. P.** (1996). Metabolism of terfenadine and its inhibition in primary human and rat hepatocytes and HepG2 cells. *Toxicology in vitro* 10: 655-663.
97. **Li, A. P.**, Reith, M. K., Rasmussen, A., Gorski, J. C., Hall, S. D., Xu, L., Kaminski, D. L., and Cheng, L. K. (1997). In vitro evaluation of drug-drug interaction potential: A comparison of rifampin, rifapentine, and rifabutin in cytochrome P450 3A induction potential in primary human hepatocytes. *Chemico-Biological Interactions* 107:17-30.
98. **Li, A. P.** and Jurima-Romet, M. (1997). Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin. *Cell Biology and Toxicology* 13: 365-374.
99. **Li, A. P.** (1998). Scientific Basis of Drug-Drug Interactions: Mechanism and preclinical evaluation. *Drug Information Journal* 32: 657-664.
100. **Li, A. P.** and Jurima-Romet, M. Overview: Scientific Basis of Pharmacokinetic Drug-Drug Interactions. in *Drug Interactions: Scientific and Regulatory Perspectives* (Li, A. P., Volume Editor), *Advances in Pharmacology*, 43: 1 - 6.
101. **A. P. Li**, D. J. Beck, L. J. Loretz, Lilly Xu, Asenath Rasmussen, Jill C. Merrill and Donald L. Kaminski (1997). Primary human hepatocytes as an *in vitro* toxicology system. In "Advances in Animal Alternatives for Safety and Efficacy Testing" (Editors: Harry Salem and Sidney A. Katz). Taylor and Francis, New York. Pp. 359-368.
102. Masubuchi, N., **Li, A. P.**, and Okazaki, O (1998). An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. *Chemico-Biol. Interact.* 114: 1-13.
103. **Li, A. P.** (1998). Preclinical evaluation of drug-drug interactions using human in vitro experimental systems. *IDrugs* 1(3):311-314.
104. **Li, A. P.** (1999). Overview: hepatocytes and cryopreservation – a personal historical prespective. *Chemico-Biological Interactions* 121: 1-6.
105. **Li, A. P.** , Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E., Silber, P. M. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in high throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. *Chemico-Biological Interactions* 121:17-36.

106. Li, A. P., Gorycki, P. D., Hengstler, J. G., Kedderis, G. L., Koebe, H. G., Rahmani, R., de Sousa, G., Silva, J. M., Skett, P. (1999). Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. *Chemico-Biological Interactions* 121:117-122.
107. Li, A. P., Hartman, N. R., Lu C., Collins, J. M., Strong, J. M. (1999). Effects of cytochrome P450 inducers on 17 β -Ethinylestradiol (EE₂) conjugation by primary human hepatocytes. *British Journal of Clinical Pharmacology*, 48:733-742.
108. Xu L, Li AP, Kaminski DL, Ruh MF (2000). 2,3,7,8 Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. *Chem Biol Interact.* 124(3):173-89.
109. Li, AP (2000). Mechanism-based preclinical approaches for the evaluation of drug-drug interactions. *Xenobiotic Metabolism and Disposition* 15:228-234.
110. MacGregor JT, Collins JM, Sugiyama Y, Tyson CA, Dean J, Smith L, Andersen M, Curren RD, Houston JB, Kadlubar FF, Kedderis GL, Krishnan K, Li AP, Parchment RE, Thummel K, Tomaszewski JE, Ulrich R, Vickers AE, Wrighton SA (2001). In vitro human tissue models in risk assessment: report of a consensus-building workshop. *Toxicol Sci.* 59(1):17-36.
111. Lu, C and Li, AP (2001). Species comparison in P450 induction: effects of dexamethasone, omeprazole and rifampin on P450 isoforms 1A and 3A in primary hepatocytes from man, Sprague-Dawley rat, minipig and beagle dog. *Chem. Biol. Interact.* 134:271-281.
112. Easterbrook, J., Fackett, D, Li, AP (2001). A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation, and testosterone 6b-hydroxylation. *Chem. Biol. Interact.* 134:243-249.
113. Li, A. P. (2002). ADME-Tox screening in drug discovery. In: *Integrated Drug Discovery Technologies* (Mei, H. Y. and Czarnik, A. W., Editors), Marcel Dekker Inc., New York and Basel. Pp. 289 – 318.
114. Li, A. P. (2002). Foreword: Evaluation of Idiosyncratic Drug Toxicity. *Chemico-Biol Interact* 2002 Nov 10:142(1-2):1-3.
115. Kapetanovic, I. M., Torchin, C. D., Strong, J. M., Yonekawa, W. D., Lu, C., Li, A. P., Dieckhaus, C. M., Santos, W. L., Macdonald, T. L., Sofia, R. D., and Kupferberg, H. J. (2002). Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. *Chem Biol Interact.* 2002 Nov 10;142(1-2):119-34.
116. Lloyd, S. , Hayden, M. J., Sakai, Y., Fackett, A., Silber, P. M., Hewitt, N. J., and Li, A. P. (2002). Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among

- cryopreserved human hepatocytes from thirty-seven donors. *Chem Biol Interact.* 2002 Nov 10;142(1-2):57-71.
117. Prabhu, S., Fackett, A., Lloyd, S., McClellan, H. A., Terrell, C. M., Silber, P. M., **Li, A. P.** (2002), Identification of glutathione conjugates of troglitazone in human hepatocytes. *Chem Biol Interact.* 142(1-2):83-97.
118. Hewitt, N. J., Lloyd, S., and **Li, A. P.** (2002). CYP3A4, glucuronyl transferase and sulfotransferases as key determinants of troglitazone cytotoxicity in human hepatocytes. *Chem Biol Interact.* 2002 Nov 10;142(1-2):83-97.
119. Shitara, Y., Itoh, T., Satoh, H., **Li, A. P.**, and Sugiyama, Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. *J. Pharmacol. Exp. Ther.* 304:610-616.
120. **Li, A. P.** A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. *Chem Biol Interact.* 2002 Nov 10;142(1-2):7-23.
121. Shitara, Y., **Li, A. P.**, Kato, Y., Lu, C., Ito, K., Itoh, T. and Sugiyama, Y. (2003). Function of uptake transporters for taurocholate and estradiol 17 β -D-glucuronide in cryopreserved human hepatocytes. *Drug Metabol. Pharmacokin.* 18:33-41.
122. **Li, A. P.** Advancing technologies for accelerated drug development. *Drug Discov Today.* 2003 Mar 1;8(5):200-2.
123. Lanika A. Brown, Linda M. Arterburn, Ana P. Miller, Nancy L. Cowger, Sonya M. Hartley, Annette Andrews, Paul M. Silber, **Albert P. Li** (2003). Maintenance of liver functions in rat hepatocytes cultured as spheroids in a rotating wall vessel. *In Vitro Cellular & Developmental Biology – Animal* 39(1): 13-20.
124. **Li, A. P.** In vitro approaches to evaluate ADMET drug properties. *Curr Top Med Chem.* 2004;4(7):701-6.
125. **Li, A. P.** In vitro experimental models for the blood-brain barrier. *Drug Discov Today.* 2004 Mar 1;9(5):204-5.
126. Hesse LM, Sakai Y, Vishnuvardhan D, **Li AP**, Von Moltke LL, Greenblatt DJ. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. *J Pharm Pharmacol.* 2003 Sep;55(9):1229-39.
127. Kier LD, Neft R, Tang L, Suizu R, Cook T, Onsurez K, Tiegler K, Sakai Y, Ortiz M, Nolan T, Sankar U, and **Li AP.** Applications of microarrays with toxicologically-relevant genes

(tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. *Mutation Research* 2004; 549: 101-113.

128. **Li, AP.** An integrated multidisciplinary approach to drug safety assessment. *Drug Discovery Today* 2004; 9(16): 687-693
129. Oleson FB, Berman CL, **Li AP.** An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. *Chem Biol Interact.* 2004 Nov 20;150(2):137-47.
130. **Li AP,** Bode C, Sakai Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. *Chem Biol Interact.* 2004 Nov 1;150(1):129-36.
131. **Li AP.** A comprehensive approach for drug safety assessment. *Chem Biol Interact.* 2004 Nov 1;150(1):27-33.
132. **Li AP.** Accurate prediction of human drug toxicity: a major challenge in drug development. *Chem Biol Interact.* 2004 Nov 1;150(1):3-7.
133. **Li AP.** Preface. *Chem Biol Interact.* 2004 Nov 1;150(1):1.
134. Zou L, Henderson GL, Harkey MR, Sakai Y, **Li A.** Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. *Phytomedicine.* 2004;11(4):285-94.
135. Zou L, Henderson GL, Harkey MR, Sakai Y, **Li A.** Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. *Phytomedicine.* 2004;11(4):285-94.
136. **Li AP.** Preclinical in vitro screening assays for drug-like properties. *Drug Discovery Today* 2005; 2: 179-195.
137. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, **Li AP,** LeCluyse E, Groothuis GM, Hengstler JG. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. *Drug Metab Rev.* 2007;39(1):159-234.
138. **Li, AP.** Human hepatocytes: isolation, cryopreservation and applications in drug development. *Chem Biol Interact.* 2007 May 20;168(1):16-29.
139. **Li, AP.** In vitro evaluation of metabolic drug-drug interactions: a descriptive and critical commentary. *Current Protocols in Toxicology* 2007 33:4.25.1-4.25.11.

140. **Li, AP.** In vitro evaluation of metabolic drug-drug interactions: concepts and practice. In: Drug-drug Interactions in Pharmaceutical Development (Editor: A. P. Li). John Wiley & Sons, Inc., 2008. Pp. 1 – 30
141. **Li, AP.** In vitro evaluation of metabolic drug-drug interactions: scientific concepts and practical considerations. In: Preclinical Development Handbook: ADME and Biopharmaceutical Properties (Editor: S. C. Gad). John Wiley & Sons, Inc., 2008. Pp. 853-877.
142. **Li, AP.** In Vitro Evaluation of Human Xenobiotic Toxicity: Scientific Concepts and the Novel Integrated Discrete Multiple Cell Co-Culture (IdMOC) Technology. ALTEX. 2008;25(1):43-9.
143. **Li, AP.** Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties: general concepts and assay procedures. ALTEX. 2008;25(1):33-42.
144. **Li, AP.** Human-based in vitro Experimental Systems for the Evaluation of Human Drug Safety. In: Hepatotoxicity – from Genomics to in vitro and in vivo Models (Editor: Saura C. Sahu, U. S. Food and Drug Administration). John Wiley & Sons, Ltd, West Essex, England.
145. **Li, AP.** Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metab Dispos. 2009 Aug;37(8):1598-603. Epub 2009 May 18.
146. **Li, AP.** Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. Chem Biol Interact. 2009 Apr 15;179(1):4-8. Epub 2008 Oct 4.
147. **Li, AP, Lu, C.** Evaluation of inhibitors of drug metabolism in human hepatocytes. In: Enzyme Inhibition in Drug Discovery and Development. (C. Lu and A. P. Li, Editors). Wiley Press, New York (2009).
148. **Li, AP.** Evaluation of drug metabolism, drug-drug interactions, and in vitro hepatotoxicity with cryopreserved human hepatocytes. *Methods Mol Biol*; 2010;640:281-94.
149. Richter, P.A., **A.P. Li**, G. Polzin, and S.K. Roy, *Cytotoxicity of eight cigarette smoke condensates in three test systems: comparisons between assays and condensates*. Regul Toxicol Pharmacol, 2010. **58**(3): p. 428-36.
150. **Li, A.P.,** *Evaluation of drug metabolism, drug-drug interactions, and in vitro hepatotoxicity with cryopreserved human hepatocytes*. *Methods Mol Biol*, 2010. **640**: p. 281-94.
151. **Li, A. P.** and U. Doshi, Higher Throughput Screening Assays for CYP3A4 Inhibition and Induction in Human Hepatocytes. *J. Biomol. Screen.* Volume: 16, Issue: 8, 2011. Pages: 903-909
152. **Li, A. P.** and U. Doshi, Higher Throughput Screening Assays for Time-Dependent Inhibition of CYP3A4 in Human Hepatocytes. *Drug Metabolism Letters*, Volume 5, Number 3, August 2011 , pp. 183-191(9).
153. **Li, A. P.,** A. Uzgare, Y. LaForge, *Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: Results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen*. *Chem. Biol. Interact.* 2012 (in press).

154. Yang Q., U. Doshi U., N. M. Li, **A. P. Li**, *Effects of Culture Duration on Gene Expression of P450 Isoforms, Uptake and Efflux Transporters in Primary Hepatocytes Cultured in the Absence and Presence of Interleukin- 6: Implications for Experimental Design for the Evaluation of Down-regulatory Effects of Biotherapeutics*. *Current Drug Metabolism*, 2012 (in press)

BOOKS

- A. P. Li** and R. H. Heflich, Editors. Genetic Toxicology. CRC Press, Boca Raton (1991).
- A. P. Li** (Editor-in-chief). Toxicity Testing: New Approaches and Applications in Human Risk Assessment. Raven Press, New York (1985).
- A. P. Li**, Editor. *Drug-Drug Interactions: Scientific and Regulatory Perspectives*. (Vol. 43, *Advances in Pharmacology Series*). Academic Press, San Diego (1997).
- A. P. Li** and Yuichi Sugiyama. *Preclinical and Clinical Evaluation of Drug-Drug Interactions*. ISE Press: Baltimore, MD. (2003).
- A. P. Li**, Editor. *Drug-Drug Interactions in Pharmaceutical Development*. Wiley Press, New York (2007).
- C. Lu and **A. P. Li**, Editors. *Enzyme Inhibition in Drug Discovery and Development*. Wiley Press, New York (2009)

SPECIAL JOURNAL ISSUES

- A. P. Li** and G. L. Kedderis, Guest Editors. Special Issue: Cytochrome P450 Induction in Primary Cultured Hepatocytes. *Chemico-Biological Interactions*, Vol. 107, Nos. 1, 2 (1997).
- A. P. Li**, Guest Editor. Special Issue of Hepatocyte Reports: Hepatocyte Cryopreservation. *Chemico-Biological Interactions*, Vol. 121 (1999).
- A. P. Li**, Guest Editor. Special Issue: Idiosyncratic Drug Toxicity. *Chemico-Biological Interactions* 142 (2002).
- A. P. Li**, Editor. Special Issue: Accurate Prediction of Human Drug Toxicity: Challenges, Strategies and Experimental Approaches. *Chemico-Biological Interactions* 150 (2004).
- A. P. Li**, Editor. Special Issue: Hepatocytes and Drug Development. *Chemico-Biological Interactions* 168 (2007).
- A. P. Li**, Editor. Special Issue: Metabolism-based Drug Toxicity. *Chemico-Biological Interactions* (2008).